NCT00055562已完成2 期
Multicenter, Randomized, Controlled, Double-Blind, Parallel-Group Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma Whose Disease Has Progressed on Treatment With DTIC, IL-2 or IFN Based Therapy
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 274
- 试验地点
- 31
研究概览
简要总结
Subjects are randomized to one of two treatment arms. All subjects are screened for eligibility within 28 days prior to randomization. The study consists of a treatment phase and a follow-up phase. Subjects will be treated in repeating 4 week cycles.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Understand and voluntarily sign an informed consent form.
- •Able to adhere to the study visit schedule and other protocol requirements.
- •Metastatic malignant melanoma now stage IV, relapsed or refractory to standard metastatic therapy.
- •Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days of starting study drug.
- •Patients with active brain disease, or newly diagnosed brain metastases, within 4 weeks prior to the start of study treatment are excluded.
排除标准
- 未提供
研究者
研究点 (31)
Loading locations...
相似试验
已完成
3 期
Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.Neoplasm MetastasisMelanomaNCT00057616Celgene274
已完成
3 期
Study to Evaluate AD04 in Adults With Alcohol Use Disorder (AUD) and Selected Serotonin Transporter PolymorphismsAlcohol Use DisorderNCT04101227Adial Pharmaceuticals302
已完成
3 期
An Study of Efficacy and Safety of ClevudineChronic Hepatitis BNCT01192854Eisai Co., Ltd.288
Unknown
不适用
Effect of a Mixture of Fibers and Carbohydrates on Intestinal Transit in Children Diagnosed With Functional ConstipationConstipation - FunctionalNCT04028258Laboratorios Ordesa120
进行中（未招募）
3 期
A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic CancerStage III Pancreatic CancerNCT03899636Angiodynamics, Inc.528